Ion Beam Applications, SA

Regulatory Filings • Feb 9, 2012

IBA HOLDS A CONFERENCE CALL ON THE PARTNERSHIP WITH SK CAPITAL PARTNERS

Louvain-La-Neuve, 9th February 2012

On 9th January 2012, IBA (Ion Beam Applications S.A.) and SK Capital Partners, a U.S. based private investment firm, announced that they entered into an agreement to create:

• IBA Molecular Imaging, a jointly-owned new company derived from IBA's molecular imaging division and
• a joint venture to equally share the development costs of the current pipeline of new imaging molecules.

A month after the signature of the said agreement, IBA invites interested parties to join a Q&A conference call.

Invitation to the conference call:

Press release | Regulated information

On 13th February, IBA will hold a public conference call for media, analysts and investors, in English, at 6:00 pm (Brussels-Paris time). Please dial in ten minutes before the conference call using the dial-in number for your area:

Dial In numbers	0800 746 68 - Belgium Toll Free 02 789 8603 – Belgium Standard Access 1 212 999 6659 – USA Standard Access +44 (0) 20 3003 2666 - Standard International Access 0808 109 0700 - UK Toll Free 1 866 966 5335 - USA Toll Free
Conference name:	SK/IBA Partnership
Start date & time	13th Feb 2012 – 6:00 pm (Brussels-Paris time)

An operator will welcome you and will take your name and company name. The related presentation will be available for download at http://www.iba-worldwide.com as from 5:30 pm on 13th February 2012.

ABOUT IBA

IBA group develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. The company is also active in the field of industrial sterilization and ionization, with decades of scientific expertise in health-related hygiene and safety. Headquartered in Belgium, IBA declared revenues of about EUR 400 million in 2010. It is present in more than 40 countries in North America, Europe and Asia and employs 2100 professionals. IBA was awarded Frost & Sullivan's European Radiopharmaceuticals Technology Leadership of the Year prize in 2010.

Press release | February 9, 2012 1 | 2

Press release | Regulated information

Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: www.iba-worldwide.com

ABOUT SK CAPITAL PARTNERS

SK Capital Partners is a private investment firm with a disciplined focus on the specialty materials, chemicals and healthcare sectors. Our integrated, multi-disciplinary team utilizes its industry, operating and investment experience to transform businesses into higher performing organizations. Located in New York (NY) and Boca Raton (FL), we are currently investing from SK Capital Partners III, L. P., a \$500 million fund of committed capital. Our portfolio companies generate revenues of over \$3.0 billion annually and employ more than 3,400 people. More information is available at www.skcapitalpartners.com

CONTACT FOR ANY TECHNICAL ISSUES Marie Gahylle IBA Corporate assistant Phone : +32 10 47 58 90 E-mail : InvestorRelations@iba-group.com

Press release | February 9, 2012 2 | 2